CFI-400945 Fumarate for Myelodysplastic Syndromes

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Myelodysplastic Syndromes+7 More
CFI-400945 Fumarate - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing an investigational drug to treat relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome. The goal is to find the best dose that is safe and tolerable for patients.

Eligible Conditions
  • Myelodysplastic Syndromes
  • Refractory Cancer
  • Relapsed Cancer
  • Leukemia, Myelocytic, Acute

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: 5 years

5 years
Evaluation of the frequency and severity of treatment-emergent adverse events in patients
Highest tolerated dose of CFI-400945 fumarate
Number of participants with response to treatment
Recommended phase 2 dose of CFI-400945 fumarate

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

1 Treatment Group

CFI-400945
1 of 1

Experimental Treatment

13 Total Participants · 1 Treatment Group

Primary Treatment: CFI-400945 Fumarate · No Placebo Group · Phase 1

CFI-400945
Drug
Experimental Group · 1 Intervention: CFI-400945 Fumarate · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,369 Previous Clinical Trials
471,880 Total Patients Enrolled
3 Trials studying Myelodysplastic Syndromes
32 Patients Enrolled for Myelodysplastic Syndromes
Karen Yee, M.D.Principal InvestigatorPrincess Margaret Cancer Centre

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: November 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.